Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

13.07
-0.3800-2.83%
Post-market: 13.200.1262+0.97%19:54 EDT
Volume:1.30M
Turnover:17.12M
Market Cap:1.23B
PE:-4.14
High:13.83
Open:13.69
Low:12.80
Close:13.45
52wk High:16.33
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:0.48
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:11.66
PE(LYR):-3.86

Loading ...

Replimune Climbs on Report of Makary's Possible Ouster From FDA

Dow Jones
·
May 09

Replimune jumps on news FDA chief behind RP1 rejection may be removed

TIPRANKS
·
May 09

BUZZ-Replimune surges after report FDA chief Makary may be ousted

Reuters
·
May 09

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:09 PM

Reuters
·
May 09

BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel

Reuters
·
May 06

FDA Commissioner Makary defends agency's decision on Replimune's drug

Reuters
·
May 05

Replimune Shares Fall 5% After FDA Commissioner Marty Makary Defends Agency's Decision on Co's Cancer Drug

THOMSON REUTERS
·
May 05

Rpt- FDA's Makary on Replimune Says Three Indepndent Teams Arrived at the Same Conclusions - CNBC

THOMSON REUTERS
·
May 05

FDA's Makary on Replimune's Drug Says IF the Clinical Trials Show That It Works, It's Going to GET Approved - CNBC

THOMSON REUTERS
·
May 05

Replimune to present IGNYTE trial survival data at ASCO annual meeting

Reuters
·
Apr 27

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire
·
Apr 27

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Reuters
·
Apr 23

Replimune rises after Wall Street Journal editorial defending RP1

TIPRANKS
·
Apr 22

Replimune Group (REPL) was downgraded to a Hold Rating at Leerink Partners

TIPRANKS
·
Apr 15

NASD Most Active Issues

Dow Jones
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune

Reuters
·
Apr 14

FDA Rejection Sparks Questions On Replimune Drug Approval Path

Benzinga_recent_news
·
Apr 14

Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%. -- Barrons.com

Dow Jones
·
Apr 13

BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma

Reuters
·
Apr 13

Replimune Group Facing 'Significant Risk' on RP1's Ongoing Phase 3 Study, Wedbush Says

MT Newswires Live
·
Apr 13